Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Reports Strong Phase II Data for Hepatitis C Drug

publication date: Mar 17, 2015
Ascletis, a US-China pharma, reported that one of its two potential treatments for hepatitis C, ASC08, a direct acting antiviral agent that Ascletis in-licensed from Roche, produced positive results in a Phase II trial. The trial enrolled Taiwanese patients. After 12 weeks of treatment, the SVR12 (sustained viral response) rate observed in genotype 1 non-cirrhotic Taiwanese patients was 94% and 100% in genotype 1b non-cirrhotic Taiwanese patients. Ascletis pointed out that Genotype 1b accounts for 98% of genotype 1 and 57% of all hepatitis C patients in mainland China. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital